ProfileGDS5678 / 1451572_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 88% 87% 86% 87% 88% 81% 87% 86% 86% 87% 86% 85% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5303386
GSM967853U87-EV human glioblastoma xenograft - Control 26.9295288
GSM967854U87-EV human glioblastoma xenograft - Control 36.6353387
GSM967855U87-EV human glioblastoma xenograft - Control 46.7752286
GSM967856U87-EV human glioblastoma xenograft - Control 56.7633187
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5714888
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6083781
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6118987
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5489686
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6240186
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.61787
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6089386
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4306585
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7494288